Cognitive Rehabilitation for Victims of War and Related Traumas With Traumatic Brain Injury and Cognitive Impairment

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMassachusetts General Hospital

About this trial

Researchers at Massachusetts General Hospital are looking to see if a program created to help improve thinking and memory can work for people affected by trauma, including asylum seekers and refugees, survivors of intimate partner violence (IPV) and others with traumatic brain injury (TBI). They're checking if this program is practical and if people find it helpful.

The study will have two groups. Participants will complete a first questionnaire and then be assigned to a group by chance. One group will participate in the program immediately and then answer the second questionnaire (approximately 3 months after the first questionnaire they did). Then they will wait and then answer the third and final questionnaire approximately 6 months after the first one.

The second group will wait and answer the second questionnaire approximately 3 months after the first one. Then they will receive the program and answer the third and final questionnaire (approximately 6 months after the first one they did.)

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Participation in cognitive rehabilitation treatment current or in past 3 months

Severe TBI or TBI only sustained under the age of 18

Diagnosis of bipolar, psychosis, active substance use, self-reported current active suicidal ideation (Potential participants can be screened again after 30 days in the case of suicidal ideation)

Trial design

Design model

Parallel

Treatments tested in this trial

  • A Trauma-informed, Paraprofessional Delivered Virtual Cognitive Rehabilitation Program

    Behavioral

    The intervention will involve 8 proposed individual sessions conducted virtually by a trained bilingual paraprofessional. The intervention will be provided in English or Spanish depending on the participant's preference. The sessions cover psychoeducation about TBI and related symptoms like depression and anxiety, and cognitive activities to address cognitive symptoms (e.g., relaxation strategies and exercises around improving attention, concentration, learning, and memory). Each session covers the topic, real-life examples and practice, and exercises to do outside of the sessions.

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Adapted cognitive rehabilitation program interventionExperimental treatment 1 intervention
Group B: Waitlist ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Acceptability of the intervention

At least 70% of participants will complete 7 or more sessions. At least 70% of participants will complete their homework. At least 80% of participants will complete the study and 12 weeks assessment. At least 60% of participants will complete the 24 weeks assessment.

Time frame
Through Intervention participation, an average of 8 weeks, and at the 12 weeks and 24 weeks follow-up questionnaires.
2

Acceptability of the intervention

At least 70% of participants will score over the midpoint in the 4-item Acceptability of Intervention Measure. The AIM scale values range from 1 to 5 with a higher score of 20. Higher scores indicate greater acceptability.

Time frame
After the intervention at the 12 weeks and 24 weeks follow-up questionnaires.
3

Feasibility of the intervention

At least 80% of people approached will agree to participate (feasibility of recruitment). At least 70% of participants will have no measures fully missing (feasibility of assessments).

Time frame
Baseline, and through Intervention participation, an average of 8 weeks.
4

Feasibility of the intervention

At least 70% of participants will score over the midpoint in the 4-item Feasibility of Intervention Measure (FIM). The FIM is a scale whose values range from 1-5 and a higher score of 20. Higher scores indicate greater acceptability.

Time frame
After the intervention at 12 weeks and 24 weeks follow-up questionnaires.

Secondary outcomes

1

Potential effectiveness on reducing cognitive impairment symptoms in objective measures

Improvement in cognitive function will be assessed through changes on Montreal Cognitive Assessment (MoCA). The MoCA's highest possible score is 30; a score of 26 and higher is considered normal and lower than this cut off will indicate possible cognitive impairment

Time frame
Baseline, 12 weeks and 24 weeks follow-up questionnaires
2

Potential effectiveness on reducing cognitive impairment symptoms in objective measures

Improvement in cognitive function will be assessed through changes on: Rowland Universal Dementia Assessment Scale (RUDAS) measure. The RUDAS maximum score is 30; a score of 23 and higher is considered normal and lower than this cut off will indicate possible cognitive impairment.

Time frame
Baseline, 12 weeks and 24 weeks follow-up questionnaires
3

Potential effectiveness on reducing cognitive impairment symptoms in subjective measures

Improvement in cognitive function will be assessed through changes in: PROMIS (Patient Reported Outcome Measurement Information System) Short Form v2.0 - Cognitive Function 8a scale. The scale uses a T score metric where 50 is the mean (the average for the United States general population) and 10 is the standard deviation above or below the mean. A higher score indicates better cognitive performance.

Time frame
Baseline, 12 weeks and 24 weeks follow-up questionnaires
4

Potential effectiveness on reducing cognitive impairment symptoms in subjective measures

Improvement in cognitive function will be assessed through changes in the cognitive questions of Neurobehavioral Symptom Inventory (NSI). The NSI total score ranges from 0 to 88 and it can provide raw scores for four domains, one of them cognitive. A higher score indicates more severe post-concussive symptoms.

Time frame
Baseline, 12 weeks and 24 weeks follow-up questionnaires

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Massachusetts General Hospital

Lead sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator